Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Learn the long-term average annual return for index funds and how it informs portfolio construction, diversification, and risk management.
27,739 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Analysts warn that Iran could use control of key internet cables as a new economic lever, risking a wave of volatilit...
Taiwan’s president emphasizes arms sales as the key deterrent to conflict, while Trump questions ongoing support, tri...
BitMine Immersion Technologies’ largest ETH purchase of the year lifts holdings to about 5.39 million ETH, reinforcin...
Peloton’s chief operations officer outlines a Navy-derived blueprint to tame volatile supply chains, emphasizing tran...
A federal class-action in Colorado expands as new homeowners join the suit against Unison. Plaintiffs allege Unison's...
The 2026 World Cup in the United States, Canada, and Mexico marks FIFA's biggest payday to date as the organization r...
When a company's chief financial officer sells stock, investors rightly pause. This article breaks down what the sale...
A sweeping elder fraud operation hinged on convincing seniors to mail cash. This in-depth guide breaks down how the s...
A deep dive into a sleeper AI infrastructure stock that could gain as data centers demand faster, cleaner connectivit...
News of potential price reductions for popular GLP-1 therapies sparked a slide in Novo Nordisk and Eli Lilly shares. ...
As markets navigate a choppy start to March 2026, traders rely on the best stock scanners screeners to turn vast data...